Albendazole Suppresses SARS‐CoV‐2 Replication by Enhancing HERC5‐Mediated ISGylation of Nucleocapsid Protein

Le résumé fourni par la source

Interferons constitute the host's primary antiviral defense system. It causes the expression of interferon-stimulated genes (ISGs), including ISG15, which modulate viral replication. Here, we identify the E3 ligase HERC5-a crucial mediator of ISGylation-as an antiviral factor against SARS-CoV-2. Analysis using mass spectrometry showed that the viral nucleocapsid (N) protein is directly bound by HERC5, which then catalyzes ISGylation occurs at four lysine residues-K61, K65, K102, and K355-found in the NTD and CTD. Functional assays confirmed that ISGylation at these sites disrupts the N protein's capacity for RNA binding and oligomerization. Conversely, the papain-like protease (PLpro) of SARS-CoV-2 cleaves ISG15 conjugates, thereby reversing N protein ISGylation. To discover small molecules that enhance the "HERC5-N" interaction, we developed a NanoLuc luciferase-based screening platform and evaluated 1815 FDA-approved drugs. Albendazole emerged as a potent enhancer of "HERC5-N" binding, further promoted N protein ISGylation, and inhibited viral replication. In vivo, Albendazole treatment reduced viral load and alleviated pulmonary inflammation in a transgenic mouse model of K18-hACE2. Together, these findings reveal the crucial functionality of N protein ISGylation in SARS-CoV-2 replication and highlight HERC5-mediated ISGylation as a promising therapeutic target.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.